1. Banerjee, S., Chakraborty, S., Das, T., Kothari, K., Samuel, G., Venkatesh, M., Pillai, M., Mathew, B., Sarma, H.D., Chaudhari, P.R., 2005. 177Lu-DOTMP, 153Sm-DOTMP, 175Yb-EDTMP and 186/188Re-CTMP: Novel Agents for Bone Pain Palliation and Their Comparison with 153Sm-EDTMP. BARC NEWSLETTER 261, 22.
2. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases;Bayouth;J. Nucl. Med.: Off. Publ., Soc. Nucl. Med.,1994
3. Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis;Biersack;J. Nucl. Med.,2011
4. Separation of no-carrier-added radioactive scandium from neutron irradiated titanium;Bokhari;J. Radioanal. Nucl. Chem.,2009
5. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease;Brenner;J. Nucl. Med.,2001